Conclusion: patient-reported outcomes are important measures of disease severity in cutaneous chronic GVHD and can assist in risk-stratifying those at highest risk of mortality. Check out associated editorial: https://t.co/odss72freX
co-authors: @DrJoelGelfand@StephanieLeeMD
Cutaneous chronic GVHD is a debilitating complication of stem cell transplant that impairs quality of life.
In new research, we examined the association of patient-reported outcomes with mortality. Published today in @JAMADerm /1
https://t.co/BnGLHe84lS
Clinically meaningful worsening in quality of life scores was associated with an adjusted odds of nonrelapse mortality increased by 9.1% (95% CI, 2.0%-16.7%; P = .01) and symptom scores by 16.4% (95% CI, 5.4%-28.5%; P = .003). /3
An important follow up study on #MedDerm residencies in the US, showing combined Med-Derm residents more comfortable with interdisciplinary care, prescribing biologics and immunosuppressives, and provide more care for the underserved! #dermtwitter
https://t.co/Z4pr9mYJcJ
Hot off the press - our new book “Fitzpatrick’s Therapeutics: A Clinician’s Guide to Dermatologic Treatment”- https://t.co/FYURTADIj0
A big thanks to all the authors & co-editors Drs. Sewon Kang, Chee Leok Goh, & Noori Kim for helping create this new bedside tool #dermtwitter
Over 100 governments in low- and middle-income countries have introduced anti-poverty cash transfer programs over the last 3 decades
In new research, we examined the effects of these initiatives on the ultimate health outcome — mortality
Published today in @Nature /1
Follow along as @EmilyBaumrinMD, discusses her research on whether the severity of skin involvement of chronic graft-versus-host-disease is a prognostic marker for poorer outcomes in patients with chronic graft-versus-host-disease #GVHD. https://t.co/9b53uujg6D @PennMedicine
Getting old enough that the continuity clinic family tree is getting kind of big!
Look at all these wonderful dermatologists doing amazing things in the field. Bring a part of their journey has been/is such an honor and joy.
#AAD2023#dermtwitter
Two phenomenal mentors: AAD Master Dermatologist Award (Dr Alice Gottlieb) @AADskin; Dr Andrew Franks Lifetime Achievement Award @MedDermSoc and mentee Emily Baumrin young investigator award @MedDermSoc @EmilyBaumrinMD
In summary,
-erythema and sclerotic chronic GVHD have distinct natural histories
-erythema is a significant predictor of DEATH
-assessing clinical severity by BSA has highest prognostic value
-current assessments are inadequate for predicting death for sclerosis
We found that severity of erythema-type chronic GVHD is a clinical prognostic marker for mortality, and that assessment by involved BSA has the highest prognostic value @PennMedicine@vdtrc @VUMCResearch @gvhd_hub#dermtwitter /1
https://t.co/W8zBxsZcun
Comparing nested prediction models, BSA severity assessments at baseline and follow-up had the best prognostic value for death. Sclerosis had no prognostic value using our current clinical assessment measures. /4
In a new study, we examine trends in transactional sex and economic outcomes during the first year of the pandemic among women at risk for HIV exposure in rural Kenya
1/6
@hthirumurthy
https://t.co/azRAGGrqIm